Pyramax® submitted to EMA for regulatory approval

MMV is proud to have partnered with Korea’s innovative pharmaceutical company Shin Poong Pharmaceutical Co Ltd. in the development of this new ACT

08 Apr 2010

The new artemisinin combination therapy (ACT) Pyramax® (a fixed-dose combination artesunate with the Mannich base antimalarial, pyronaridine) was developed by MMV in collaboration with Shin Poong Pharmaceutical Co Ltd. The registration dossier for this promising new antimalarial was submitted to the European Medicines Agency (EMA) for regulatory approval under Article 58 of a dual indication against P. falciparum and blood stages of P. vivax malaria.

Phase III data published in The Lancet, April 24, 2010

There is a need for new artemisinin-based combination therapies that are convenient, effective and safe. This Phase III study compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P. falciparum malaria, and showed it to be non-inferior. If you are a registered user on The Lancet's website:

Read the article

Read a comment on the article.